RT Journal Article
SR Electronic
T1 The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.22.20199422
DO 10.1101/2020.09.22.20199422
A1 Almadhi, Marwa Ali
A1 Abdulrahman, Abdulkarim
A1 Alawadhi, Abdulla
A1 A.Rabaan, Ali
A1 AlQahtani, Manaf
YR 2020
UL http://medrxiv.org/content/early/2020/09/22/2020.09.22.20199422.abstract
AB The current COVID-19 pandemic has affected more than 22 million cases and caused immense burdens on governments and healthcare systems worldwide. Since its emergence in December 2019, research has been focused on ways to not only treat the infected but also identify those at risk and prevent spread. There is currently no known biological biomarker that can predict the risk of being infected. A growing set of studies have emerged that show an association between ABO blood group and the risk of COVID-19 infection. In this study, we used retrospective observational data in Bahrain to investigate the association between ABO blood group and risk of infection as well as susceptibility to a more severe ICU-requiring infection. We found that individuals with blood group B were at a higher risk of infection, while those with blood group AB were at a lower risk. No association was observed between blood group and the risk of a severe ICU-requiring COVID-19 infection. We extended the analysis to study the association by antibodies present; anti-a (blood groups B and O) and anti-b (blood groups A and O). Antibodies were not found to be associated with either risk of infection or susceptibility to severe infection. The current study, along with the variation in blood group association results, indicates that blood group may not be the most ideal biomarker to predict risk of COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval received from National COVID-19 Research CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.